Antiplatelet medications play a critical role in cardiovascular and neurovascular care. When it comes to managing patients on antiplatelet therapies, the lab plays a critical role for physicians—a significant fact considering that up to one-third of all patients may not receive the expected antiplatelet effect.1

Furthermore, patients who are not responding adequately to their antiplatelet therapy may be at 5 to 10 times greater risk for ischemic events.2-5

Additionally, cardiac surgery is frequently delayed for an average of five to seven days in order to minimize complications resulting from platelet inhibiting drugs.

Thus, it is important to assess a patient’s response to antiplatelet medications.

0
Why the VerifyNow Solution?

1) Unlike other platelet function tests that measure bleeding time or diagnose platelet disorders, the VerifyNow® System measures the effect of the antiplatelet medication, which helps to assess an individual patient’s response to antiplatelet therapy after antiplatelet medications have been administered.

2) The VerifyNow System’s clinical utility and analytical performance is backed by over 60 peer-reviewed studies. It is the most clinically studied of any rapid method to assess platelet reactivity. The VerifyNow System provides laboratorians and clinicians the clinical and analytical data to appropriately select and integrate the VerifyNow System and test results into practice.

3) The VerifyNow System provides you with an easy and rapid solution to assess a patient’s response:

  • Provides results in minutes*
  • Requires little hands-on time
  • Uses whole blood, closed tube samples
  • Requires no pipetting or sample preparation, thus reducing the risk of pre-analytical error
  • Replaces more cumbersome and time-consuming methods
  • Is reimbursable through CPT and ICD 9 codes

*additional sample incubation required, varies by test

The VerifyNow System help assess a patient’s response to the following antiplatelet medications:

Click here to learn why you should join the growing number of laboratorians who utilize the VerifyNow System in their facility.

  • Dupont, AG. et al. Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome. Thromb Res. 2009 May;124(1):6-13.
  • Patti, G. et al. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention. Results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol. 2008; 52:1128–33.
  • Marcucci, R. et al. Cardiovascular death and nonfatal myocardial Infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay. A 12-Month follow-Up. Circulation. 2009;119(2):237-42.
  • Cuissett, T. et al. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am J Cardiol;2008 Jun 15;101(12):1700-3.
  • Price, MJ. et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008 Apr;29(8):992-1000